Mediwhale

About Mediwhale

Mediwhale develops AI medical devices that analyze retinal images to predict cardiovascular, kidney, and eye disease risks early. The company has regulatory-approved solutions deployed in hospitals and clinics globally, with a focus on cardiometabolic disease prevention and low-radiation, quick retinal assessments. Based in Seoul, they market products such as Dr.Noon CVD, CKD, and Fundus, serving healthcare providers across regions including Korea, the UAE, the UK, and Italy.